B2Digital Incorporated (OTCMKTS: BTDG) Reports Record Growth For Live Events and Gym Segments

July 16, 2021

B2Digital Incorporated (OTCMKTS: BTDG)  has announced interim results for the quarter ended June 30, 2021, in which the company reported revenues at a rate of $2.1M per year. B2Digital almost matched 2019 performance  B2Digital CEO & Founder, Greg P. Bell said, “ It’s important to note that this data still does not yet reflect the full reopening dynamic because our live event crowds for Q1 were still being capped well…

Read More >>

Evoke Pharma Inc. (NASDAQ: EVOK) Launches Physician and Patient Experience Program for GIMOTI

July 15, 2021

Evoke Pharma Inc. (NASDAQ: EVOK) dropped 3.17% after the company announced the commencement of more marketing initiatives focusing on introducing physician and patient experience programs for GIMOTI, its nasal spray of relief of acute and recurrent diabetic gastroparesis (DGP) symptoms.  Evoke launches GIMOTI experience program  The program will offer GIMOTI samples mainly to advance practice practitioners and targeted gastroenterologists. Most importantly, the program will expand GIMOTI awareness and trials for…

Read More >>

Novo Integrated Sciences Inc. (NASDAQ: NVOS) Reports 129% YoY Revenue Growth In Q3 2021

July 15, 2021

Novo Integrated Sciences Inc. (NASDAQ: NVOS) has announced its Q3 2021 ended May 31, 2021, financial results in which the company reported revenue of $2.38 million, a 129.3% YoY increase.  The easing of COVID-19 pandemic restriction helped drive revenue growth  The revenue increase is attributed to the easing of COVID-19 related restrictions resulting in the company’s practitioners providing more in-person services to more patients compared to the period between March…

Read More >>

Presidio Property Trust (NASDAQ: SQFT) Closes $10 Million At-the-Market Direct Offering

July 15, 2021

Presidio Property Trust (NASDAQ: SQFT) has closed a registered direct offering of 1 million of its Series A common shares, warrants to buy up to 1 million Predisio common shares, and pre-funded warrants to purchase 1 million shares of the company’s common stock.  President announces registered direct offering  The company sells each common share and accompanies ordinary stock warrants at an offering price of $5. At the same time, Presidio…

Read More >>

Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) Expands Study Sites For Seclidemstat Dose Expansion Trial

July 15, 2021

Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) has announced the addition of Fox Chase Cancer Center in Philadelphia, Pennsylvania, as an active study site for the ongoing clinical trial dose-expansion phase. The company evaluates its flagship candidate, seclidemstat, to treat patients with advanced FET-rearranged and refractory or relapsed Ewing sarcomas.  Salarius to evaluate seclidemstat in Ewing sarcoma  Fox Chase’s addition expands the participating active trial site number to nine for the open-label…

Read More >>

Martin Midstream Partners L.P (NASDAQ: MMLP) Reports Net Income of $2.5 Million In Q1 2021

July 15, 2021

Martin Midstream Partners L.P (NASDAQ: MMLP) had a near bankruptcy miss last year, but as the company continues deleveraging its offering, more significant returns.  The company’s 2020 guidance could generate considerable cash flow, thus helping cut net debt.  Martin Midstream Partners ‘ operations impacted by Texas Winter storm  Despite the company’s near-miss with bankruptcy, it saw distributions drop almost to nothing with a less than 1% yield. In addition, the…

Read More >>

Hoth Therapeutics Inc (NASDAQ: HOTH) Announce Positive Results From HT-003 Assets Group

July 15, 2021

Hoth Therapeutics Inc (NASDAQ: HOTH) announced that the HT-003 assets group had fetched positive results in the therapeutic model for Vivo acne. The model displayed HT-003’s capability in bringing down the expression for receptor 2 (TLR2), which is among the most significant pathways meant for acne pathophysiology.  About the study results Additionally, the study underscored HT-003’s capability in bringing down the cytokines’ expression, which is helpful for acne pathophysiology. These…

Read More >>

Genocea Biosciences Inc (NASDAQ: GNCA) Starts Phase I/IIa TiTAN study

July 15, 2021

Genocea Biosciences Inc (NASDAQ: GNCA) announced yesterday that it has kicked off phase I/IIa TiTAN study and has dosed its first patient. The study is meant for the investigation of T-cell therapy, which is a neoantigen-targeted therapy called GEN-011. The company underscored that the FDA has earlier accepted GEN-011’s NDA or new drug application for starting phase I/IIa study. The study was approved for patients who missed inhibitor therapy at…

Read More >>

Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) Announces New Chief Commercial Officer

July 15, 2021

Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) announced recently that Anna Diaz Triola is appointed as the company’s Chief Commercial Officer. He assumed responsibilities with effect from July 19, 2021. The clinical-stage biopharmaceutical company develops and discovers antibacterial products. In his new position, Anna Diaz Triola will be responsible for commercial strategy, driving it for marketing and sales operations for the U.SUS.  Gearing up for product commercialization  The company is in…

Read More >>

CLPS Inc (NASDAQ: CLPS) Signs Definitive Agreement With Unidev For I.T.IT Solutions Delivery Enhancement

July 15, 2021

CLPS Inc (NASDAQ: CLPS) announced yesterday that it signed a definitive agreement with UniDev or Beijing UniDev Software Co., Ltd. through its subsidiary. Univ is the It solutions and services based company with its headquarters in Beijing. CLPS has signed the agreement through ChinaLink Professional Services Co. Ltd., which will also hold UniDev’s 15% ownership stake.  What’s the deal? Univ is the firm that’s focussed on extensive digital transformation, customizing…

Read More >>